New database of neuro-degenerative diseases launched
A new database of more than 4,000 Alzheimer’s disease patients who have participated in 11 industry-sponsored clinical trials was released by the Coalition Against Major Diseases (CAMD). This database will combine clinical trials to be shared by pharmaceutical companies and made available to researchers.
The database will allow researchers to predict the course of Alzheimer’s, Parkinson’s, Huntington’s and other neuro-degenerative diseases, thereby enabling the design of more efficient clinical trials, according to CAMD. Patient identifiers will not be included in the database, thereby ensuring patient privacy.
CAMD is a formal consortium of pharmaceutical companies, research foundations and patient advocacy/voluntary health associations, with advisors from government research and regulatory agencies, including the FDA, the European Medicines Agency, the National Institute of Neurological Disorders and Stroke and the National Institute on Aging. CAMD is led and managed by the non-profit Critical Path Institute (C-Path), which is funded by a cooperative agreement with the FDA and a matching grant from Science Foundation Arizona.
The FDA has supported and participated in this “public-private partnership from its inception,” said Joshua Sharfstein, MD, principal deputy commissioner of the FDA. “The agency is strongly committed to CAMD and other regulatory science collaborations that can speed safe and effective treatments to the public.”
The database will allow researchers to predict the course of Alzheimer’s, Parkinson’s, Huntington’s and other neuro-degenerative diseases, thereby enabling the design of more efficient clinical trials, according to CAMD. Patient identifiers will not be included in the database, thereby ensuring patient privacy.
CAMD is a formal consortium of pharmaceutical companies, research foundations and patient advocacy/voluntary health associations, with advisors from government research and regulatory agencies, including the FDA, the European Medicines Agency, the National Institute of Neurological Disorders and Stroke and the National Institute on Aging. CAMD is led and managed by the non-profit Critical Path Institute (C-Path), which is funded by a cooperative agreement with the FDA and a matching grant from Science Foundation Arizona.
The FDA has supported and participated in this “public-private partnership from its inception,” said Joshua Sharfstein, MD, principal deputy commissioner of the FDA. “The agency is strongly committed to CAMD and other regulatory science collaborations that can speed safe and effective treatments to the public.”